Copyright
©The Author(s) 2021.
World J Gastroenterol. Apr 21, 2021; 27(15): 1524-1530
Published online Apr 21, 2021. doi: 10.3748/wjg.v27.i15.1524
Published online Apr 21, 2021. doi: 10.3748/wjg.v27.i15.1524
Ref. | Study period | Database | Indication | Components of TO | TO rates |
Merath et al[3], 2019 | 2013-2015 | Medicare | Benign and malignant hepatopancreatic lesions | No complications. No prolonged LOS. No 90-d mortality. No 90-d readmission | 44.0% |
Merath et al[4], 2020 | 1993-2015 | Multi-institutional ICC database | Intrahepatic cholangiocarcinoma | R0 resection No transfusion. No complications. No prolonged LOS. No 30-d mortality. No 30-d readmission | 25.5% |
Tsilimigras et al[5], 2020 | 2000-2015 | Multi-institutional HCC database | Hepatocellular carcinoma | R0 resection No reoperation. No complications (Clavien-Dindo ≥ III) No prolonged LOS. No 90-d mortality. No 90-d readmission | 62.3% |
Heidsma et al[15], 2020 | 2000-2016 | US Neuroendocrine Tumor Study Group database | Pancreatic neuroendocrine tumors | R0 resection No complications (Clavien-Dindo ≥ III). No prolonged LOS. No 90-d mortality. No 90-d readmission | 49.3% |
- Citation: Tsilimigras DI, Pawlik TM, Moris D. Textbook outcomes in hepatobiliary and pancreatic surgery. World J Gastroenterol 2021; 27(15): 1524-1530
- URL: https://www.wjgnet.com/1007-9327/full/v27/i15/1524.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i15.1524